Acetylcholinesterase inhibitors (AChEIs) are pivotal in managing Alzheimer's disease and other dementias by impeding the enzyme acetylcholinesterase. This enzyme normally degrades acetylcholine, a neurotransmitter crucial for cognitive functions like memory and learning. In Alzheimer's, a deficit of acetylcholine arises from the loss of cholinergic neurons. AChEIs help sustain higher acetylcholine levels in the brain, offering temporary relief from cognitive symptoms such as memory loss and confusion. While they do not halt or reverse disease progression, these medications can significantly enhance quality of life. Common AChEIs include donepezil, rivastigmine, and galantamine, each with potential side effects like nausea and insomnia. Effective management requires ongoing monitoring and adjustments by healthcare providers to optimize therapeutic benefits.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China